Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sumatriptan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D known ✓ | P28221 | 9/20 | 0.85 |
| ▸ | HTR1B known ✓ | P28222 | 8/20 | 0.85 |
| ▸ | HTR1A | P08908 | 10/20 | 0.85 |
| ▸ | HTR2A | P28223 | 4/20 | 0.85 |
| ▸ | HTR2C | P28335 | 3/20 | 0.85 |
| ▸ | HTR7 | P34969 | 2/20 | 0.85 |
| ▸ | HTR5A | P47898 | 2/20 | 0.85 |
| ▸ | HTR2B | P41595 | 2/20 | 0.85 |
| ▸ | HTR1E | P28566 | 1/20 | 0.85 |
| ▸ | HTR1F | P30939 | 1/20 | 0.85 |
| ▸ | HTR3A | P46098 | 1/20 | 0.85 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.85 |
| ▸ | HTR6 | P50406 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sumatriptan SCHEMBL2404748 | 1.00 | HTR1A (0.85) | HTR1AHTR1DHTR1BHTR2AHTR2C | |
| Sumatriptan SCHEMBL2405528 | 1.00 | HTR1A (0.85) | HTR1AHTR1DHTR1BHTR2AHTR2C | |
| Sumatriptan SCHEMBL41674 | 1.00 | HTR1A (0.85) | HTR1AHTR1DHTR1BHTR2AHTR2C | |
| Sumatriptan SCHEMBL1556482 | 1.00 | HTR1A (0.85) | HTR1AHTR1DHTR1BHTR2AHTR2C | |
| Sumatriptan SCHEMBL27887904 | 0.99 | HTR1A (0.84) | HTR1AHTR1DHTR1BHTR2AHTR2C | |
| Sumatriptan SCHEMBL4132936 | 0.99 | HTR1A (0.84) | HTR1AHTR1DHTR1BHTR2AHTR2C | |
| Sumatriptan SCHEMBL6684827 | 0.99 | HTR1A (0.84) | HTR1AHTR1DHTR1BHTR2AHTR2C | |
| Sumatriptan SCHEMBL6688024 | 0.97 | HTR1A (0.80) | HTR1AHTR1DHTR1BHTR2AHTR2C | |
| Sumatriptan SCHEMBL4308781 | 0.97 | HTR1A (0.80) | HTR1AHTR1DHTR1BHTR2AHTR2C | |
| Sumatriptan SCHEMBL4311406 | 0.97 | HTR1A (0.80) | HTR1AHTR1DHTR1BHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| US-20250242092-A1 | SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS | SIO2 MEDICAL PRODUCTS INC (US) | 2025-07-31 | — | — | US | claimed |
| US-12257371-B2 | SiOx barrier for pharmaceutical package and coating process | SIO2 MEDICAL PRODUCTS, LLC (US) | 2025-03-25 | — | — | US | claimed |
| US-20240074944-A1 | PECVD COATED PHARMACEUTICAL PACKAGING | OAKTREE FUND ADMINISTRATION, LLC | 2024-03-07 | — | — | US | claimed |
| CN-117241773-A | Polymer medicine bottle with standard external dimensions and reduced internal volume | SIO2医疗产品有限公司 | 2023-12-15 | — | — | CN | claimed |
| US-20230303305-A1 | METHOD AND PACKAGE FOR REDUCING THE DEGRADATION OF A DRUG AND/OR EXCIPIENT, E.G. POLYSORBATE STABILIZER, IN A PHARMACEUTICAL PRODUCT | OAKTREE FUND ADMINISTRATION, LLC | 2023-09-28 | — | — | US | claimed |
| EP-4247316-A1 | POLYMER VIALS HAVING STANDARD EXTERNAL DIMENSIONS AND REDUCED INTERNAL VOLUME | SiO2 Medical Products, Inc. (US) | 2023-09-27 | — | — | EP | claimed |
| CN-116782865-A | Atomic layer deposition coated pharmaceutical packages, improved syringes and vials, e.g., for lyophilization/cold chain drugs/vaccines | SIO2医药产品公司 | 2023-09-19 | — | — | CN | claimed |
| US-20230277415-A1 | POLYMER VIALS HAVING STANDARD EXTERNAL DIMENSIONS AND REDUCED INTERNAL VOLUME | SIO2 MEDICAL PRODUCTS, INC. | 2023-09-07 | — | — | US | claimed |
| US-20230263957-A1 | ATOMIC LAYER DEPOSITION COATED PHARMACEUTICAL PACKAGING AND IMPROVED SYRINGES AND VIALS, E.G. FOR LYOPHILIZED/COLD-CHAIN DRUGS/VACCINES | OAKTREE FUND ADMINISTRATION, LLC | 2023-08-24 | — | — | US | claimed |
| US-11724860-B2 | Passivation, pH protective or lubricity coating for pharmaceutical package, coating process and apparatus | SIO2 MEDICAL PRODUCTS, INC. (US) | 2023-08-15 | — | — | US | claimed |
| US-11684546-B2 | PECVD coated pharmaceutical packaging | SIO2 MEDICAL PRODUCTS, INC. (US) | 2023-06-27 | — | — | US | claimed |
| EP-4188996-A1 | METHOD AND PACKAGE FOR REDUCING THE DEGRADATION OF A DRUG AND/OR EXCIPIENT, E.G. POLYSORBATE STABILIZER, IN A PHARMACEUTICAL PRODUCT | SiO2 Medical Products, Inc. (US) | 2023-06-07 | — | — | EP | claimed |
| EP-4168068-A1 | ATOMIC LAYER DEPOSITION COATED PHARMACEUTICAL PACKAGING AND IMPROVED SYRINGES AND VIALS, E.G. FOR LYOPHILIZED/COLD-CHAIN DRUGS/VACCINES | SiO2 Medical Products, Inc. (US) | 2023-04-26 | — | — | EP | claimed |
| US-20220244247-A1 | PECVD COATED PHARMACEUTICAL PACKAGING | OAKTREE FUND ADMINISTRATION, LLC | 2022-08-04 | — | — | US | claimed |
| WO-2022109619-A1 | POLYMER VIALS HAVING STANDARD EXTERNAL DIMENSIONS AND REDUCED INTERNAL VOLUME | SIO2 MEDICAL PRODUCTS, INC. (US) | 2022-05-27 | — | — | WO | claimed |
| US-20220161969-A1 | PASSIVATION, pH PROTECTIVE OR LUBRICITY COATING FOR PHARMACEUTICAL PACKAGE, COATING PROCESS AND APPARATUS | OAKTREE FUND ADMINISTRATION, LLC | 2022-05-26 | — | — | US | claimed |
| US-11298293-B2 | PECVD coated pharmaceutical packaging | SIO2 MEDICAL PRODUCTS, INC. (US) | 2022-04-12 | — | — | US | claimed |
| US-20260139378-A1 | PULSED PLASMA ENHANCED CHEMICAL VAPOR DEPOSITION PROCESS, SYSTEM, AND COATED VESSELS | SIO2 MEDICAL PRODUCTS INC (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2022020512-A1 | BAG FOR EASY DRAINAGE AND MANIPULATION | W. L. GORE & ASSOCIATES, INC. (US) | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260139378-A1 | PULSED PLASMA ENHANCED CHEMICAL VAPOR DEPOSITION PROCESS, SYSTEM, AND COATED VESSELS | VEGFA, FLT4, FLT1 | HTR1D 1747/4885HTR1B 2409/4885HTR1A 2362/4885 |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | MEN1, MYO1G, IL2 | HTR1D 1884/4885HTR1B 1797/4885HTR1A 2363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.